Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Pacira Pharmaceuticals (DE:82P)
FRANKFURT:82P
RESEARCH TOOLSreports
Holding DE:82P?
Track your performance easily
82P Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€10.70 - €32.20
Previous Close€15.2
Volume0.00
Average Volume (3M)243.00
Market Cap
€718.99M
Enterprise Value€942.19M
Total Cash (Recent Filing)$404.23M
Total Debt (Recent Filing)$648.60M
Price to Earnings (P/E)―
Beta0.13
Next Earnings
Oct 31, 2024EPS Estimate
€0.66Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding46,126,946
10 Day Avg. Volume0
30 Day Avg. Volume243
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)0.82
Price to Sales (P/S)1.13
Price to Cash Flow (P/CF)3.70
P/FCF Ratio3.60
Enterprise Value/Market CapN/A
Enterprise Value/Revenue1.36
Enterprise Value/Gross Profit1.92
Enterprise Value/Ebitda6.69
Forecast
1Y Price Target
€17.07Price Target Upside12.33% Upside
Rating ConsensusHold
Number of Analyst Covering9
Pacira Pharmaceuticals News
PremiumCompany Announcements
Pacira Pharmaceuticals Announces CFO Transition and Interim Replacement
Bulls Say, Bears Say
Bulls Say
Financial PerformancePCRX delivered solid 2Q24 results that beat Street expectations and maintained pace to meet 2024 guidance.
Legal StrategyPacira has four additional OB-listed patents in earlier-stage litigation versus eVenus, and the recent ruling does not invalidate those.
Market PerceptionAnalyst believes the market is overreacting to the court ruling and sees the stock weakness as wildly overdone.
Bears Say
Financial UncertaintyWith now a path for generics to enter the market, a substantial decline in Pacira’s top and bottomline is expected, and no clear path for recovery is seen.
Market CompetitionExparel composes ~80% of PCRX’s revenue, the vast majority of which will likely get eroded if PCRX can’t successfully defend other patents.
Patent IssuesThe U.S. District Court for the District of New Jersey ruled that patent #11,033,495 ('495) on Exparel is invalid.
---
Options Prices
Currently, No data available
---
Ownership Overview
1.39% Insiders
32.81% Mutual Funds
0.36% Other Institutional Investors
25.27% Public Companies and
Individual Investors
82P FAQ
What was Pacira Pharmaceuticals’s price range in the past 12 months?
Pacira Pharmaceuticals lowest stock price was €10.70 and its highest was €32.20 in the past 12 months.
What is Pacira Pharmaceuticals’s market cap?
Currently, no data Available
When is Pacira Pharmaceuticals’s upcoming earnings report date?
Pacira Pharmaceuticals’s upcoming earnings report date is Oct 31, 2024 which is in 12 days.
How were Pacira Pharmaceuticals’s earnings last quarter?
Pacira Pharmaceuticals released its earnings results on Jul 30, 2024. The company reported €0.813 earnings per share for the quarter, beating the consensus estimate of €0.638 by €0.174.
Is Pacira Pharmaceuticals overvalued?
According to Wall Street analysts Pacira Pharmaceuticals’s price is currently Undervalued.
Does Pacira Pharmaceuticals pay dividends?
Pacira Pharmaceuticals does not currently pay dividends.
What is Pacira Pharmaceuticals’s EPS estimate?
Pacira Pharmaceuticals’s EPS estimate is €0.66.
How many shares outstanding does Pacira Pharmaceuticals have?
Pacira Pharmaceuticals has 46,126,945 shares outstanding.
What happened to Pacira Pharmaceuticals’s price movement after its last earnings report?
Pacira Pharmaceuticals reported an EPS of €0.813 in its last earnings report, beating expectations of €0.638. Following the earnings report the stock price went up 7.527%.
Which hedge fund is a major shareholder of Pacira Pharmaceuticals?
Among the largest hedge funds holding Pacira Pharmaceuticals’s share is Ardsley Advisory Partners. It holds Pacira Pharmaceuticals’s shares valued at 17M.
---
Pacira Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
€17.07 (12.33% Upside)
€17.07 (12.33% Upside)
Blogger Sentiment
Bullish
DE:82P Sentiment 100%
Sector Average 70%
Sector Average 70%
Insider Transactions
Bought Shares
Worth $215.7K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-40.51%
12-Months-Change
Fundamentals
Return on Equity
7.54%
Trailing 12-Months
Asset Growth
6.77%
Trailing 12-Months
Company Description
Pacira Pharmaceuticals
Pacira Biosciences, Inc. develops and manufactures injectable therapeutic products. The firm engages in the development, commercialization and manufacture of pharmaceutical products for use in postsurgical outcomes for acute care practitioners and their patients. Its flagship product, EXPAREL, redefines pain management after surgery as an opioid-free alternative indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia. The company was founded in December 2006 and is headquartered in Parsippany, NJ.
---
82P Company Deck
---
82P Earnings Call
Q2 2024
0:00 / 0:00
---
82P Stock 12 Month Forecast
Average Price Target
€17.07
▲(12.33% Upside)
Technical Analysis
Pacira Pharmaceuticals
―
Supernus Pharmaceuticals
―
ACADIA Pharmaceuticals
―
Axsome Therapeutics
―
Dr Reddy's Laboratories
―
Best Analysts Covering 82P
1 Year
1 Year Success Rate
13/40 ratings generated profit
1 Year Average Return
-8.28%
reiterated a buy rating 2 months ago
Copying Oren Livnat's trades and holding each position for 1 Year would result in 32.50% of your transactions generating a profit, with an average return of -8.28% per trade.
---